The role of ozonized oil and a combination of tobramycin/dexamethasone eye drops in the treatment of viral conjunctivitis: a randomized clinical trial.
Inflammation
Ozonized oil eye drops
Therapy
Viral conjunctivitis
Journal
International ophthalmology
ISSN: 1573-2630
Titre abrégé: Int Ophthalmol
Pays: Netherlands
ID NLM: 7904294
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
17
03
2020
accepted:
30
06
2020
pubmed:
23
7
2020
medline:
22
6
2021
entrez:
23
7
2020
Statut:
ppublish
Résumé
To determine whether topical tobramycin 0.3%/dexamethasone 0.1% plus ozonized oil eye drops reduces clinical signs and infectious viral titers of presumed viral conjunctivitis more than tobramycin/dexamethasone eye drops alone. Prospective, single-blind, randomized, parallel-groups trial. Eighty patients with a clinical diagnosis of presumed viral conjunctivitis were randomizedly divided into two treatment groups: a study group and a control group, 40 for each group. Patients in the study group received topical tobramycin 0.3%/dexamethasone 0.1% eye drops, plus ozonized oil eye drops, both four times daily; patients in the control group received only topical tobramycin 0.3%/dexamethasone eye drops four times daily. The treatment was for seven days in both groups. Swabs were taken from the conjunctival fornix for adenovirus PCR analysis on the day of recruitment and at seven days follow-up. Clinical signs were also recorded on the day of recruitment and at follow-up examination: the main outcomes were conjunctival injection and conjunctival chemosis, graded on a 4-point clinical scale, presence or absence of superficial punctate keratitis and subepithelial corneal infiltrates. No statistically significant difference was reached in adenoviral infection negativization between the two groups, although the study group showed a higher number of PCR negative results at seven days follow-up. PCR real time detected adenoviral infection in 17 of 24 patients on the day of recruitment and it was positive in 4 patients on the seventh day (viral positivity reduction of 76%). In the control group PCR was positive for adenovirus in 18 of 24 patients on the day of recruitment and in 7 patients at seven days follow-up (reduction of 61%). There was statistically significant difference on conjunctival clinical signs between the study and control groups. Significant difference was also found on superficial punctate keratitis resolution between the study and the control group. In the former superficial punctate keratitis was detected in 14 eyes on the first day and in 5 eyes after seven days while in the latter superficial punctate keratitis was found in 124 eyes on the first day and in 6 eyes on the seventh day. No difference was found in subepithelial corneal infiltrates appearance between the two groups. The use of ozonized-oil containing eye drops in combination with topical tobramycin 0.3%/dexamethasone 0.1% eye drops four times daily seems to reduce the signs of conjunctivitis, and the duration of viral infection, although it does not affect the subepithelial corneal infiltrates appearance.
Identifiants
pubmed: 32696102
doi: 10.1007/s10792-020-01503-4
pii: 10.1007/s10792-020-01503-4
pmc: PMC7669761
doi:
Substances chimiques
Anti-Bacterial Agents
0
Ophthalmic Solutions
0
Dexamethasone
7S5I7G3JQL
Tobramycin
VZ8RRZ51VK
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
3209-3215Références
Azari AA, Barney NP (2013) Conjunctivitis: a systematic review of diagnosis and treatment. JAMA 310(16):1721–1729
pubmed: 24150468
pmcid: 4049531
Ford E, Nelson KE, Warren D (1987) Epidemiology of epidemic keratoconjunctivitis. Epidemiol Rev 9:244–261
pubmed: 2824228
Hillenkamp J, Reinhard T, Ross RS, Böhringer D, Cartsburg O, Roggendorf M, De Clercq E, Godehardt E, Sundmacher R (2002) The effects of cidofovir 1% with and without cyclosporin A 1% as a topical treatment of acute adenoviral keratoconjunctivitis: a controlled clinical pilot study. Ophthalmology 109:845–850
pubmed: 11986086
Teuchner B, Nagl M, Schidlbauer A, Ishiko H, Dragosits E, Ulmer H, Aoki K, Ohno S, Mizuki N, Gottardi W, Larcher C (2005) Tolerability and efficacy of N-chlorotaurine in epidemic keratoconjunctivitis—a double-blind, randomized, phase-2 clinical trial. J Ocul Pharmacol Ther 21:157–164
pubmed: 15857282
Romanowski EG, Gordon YJ (2000) Efficacy of topical cidofovir on multiple adenoviral serotypes in the New Zealand rabbit ocular model. Invest Ophthalmol Vis Sci 41:460–463
pubmed: 10670476
Jhanji V, Chan TC, Li EY, Agarwal K, Vajpayee RB (2015) Adenoviral keratoconjunctivitis. Surv Ophthalmol 60:435–443
pubmed: 26077630
Garcia-Zalisnak D, Rapuano C, Sheppard JD, Davis AR (2018) Adenovirus ocular infections: prevalence pathology, pitfalls, and practical pointers. Eye Contact Lens 44(Suppl 1):S1–S7
pubmed: 29664772
Berkelman RL, Holland BW, Anderson RL (1982) Increased bactericidal activity of dilute preparations of povidone-iodine solutions. J Clin Microbiol 15(4):635–639
pubmed: 7040461
pmcid: 272159
Isenberg SJ, Apt L, Yoshimori R, Pham C, Lam NK (1997) Efficacy of topical povidone-iodine during the first week after ophthalmic surgery. Am J Ophthalmol 124(1):31–35
pubmed: 9222229
Mohan N, Gupta V, Tandon R, Gupta SK, Vajpayee RB (2001) Topical ciprofloxacin-dexamethasone combination therapy after cataract surgery: randomized controlled clinical trial. J Cataract Refract Surg 27(12):1975–1978
pubmed: 11738913
Speaker MG, Menikoff JA (1991) Prophylaxis of endophthalmitis with topical povidone-iodine. Ophthalmology 98(12):1769–1775
pubmed: 1775308
Romanowski EG, Roba LA, Wiley L, Araullo-Cruz T, Gordon YJ (1996) The effects of corticosteroids on adenoviral replication. Arch Ophthalmol 114:581–585
pubmed: 8619769
Spadea L, Tonti E, Spaterna A, Marchegiani A (2018) Use of ozone-based eye drops: a series of cases in veterinary and human spontaneous ocular pathologies. Case Rep Ophthalmol 9(2):287–298
pubmed: 29928225
pmcid: 6006625
Valacchi G, Fortino V, Bocci V (2005) The dual action of ozone on the skin. Br J Dermatol 153(6):1096–1100
pubmed: 16307642
Mohamed MSM, Abdallah AA, Mahran MH, Shalaby AM (2018) Potential alternative treatment of ocular bacterial infections by oil derived from Syzygium aromaticum flower (Clove). Curr Eye Res 43(7):873–881
pubmed: 29634373
Chigbu DI, Labib BA (2018) Pathogenesis and management of adenoviral keratoconjunctivitis. Infect Drug Resist 11:981–993
pubmed: 30046247
pmcid: 6054290
Gigliotti F, Williams WT, Hayden FG, Hendley JO, Benjamin J, Dickens M, Gleason C, Perriello VA, Wood J (1981) Etiology of acute conjunctivitis in children. J Pediatr 98:531–536
pubmed: 6970802
Ishii K, Nakazono N, Fujinaga K, Fujii S, Kato M, Ohtsuka H, Aoki K, Chen CW, Lin CC, Sheu MM, Lin KH, Oum BS, Lee SH, Chun CH, Yoshii T, Yamazaki S (1987) Comparative studies on aetiology and epidemiology of viral conjunctivitis in three countries of East Asia-Japan, Taiwan and South Korea. Int J Epidemiol 16:98–103
pubmed: 3032816
Woodland RM, Darougar S, Thaker U, Cornell L, Siddique M, Wania J, Shah M (1992) Causes of conjunctivitis and keratoconjunctivitis in Karachi, Pakistan. Trans R Soc Trop Med Hyg 86:317–320
pubmed: 1412664
Torres Rojas G, Goyenechea A, Savon C, Valdes O, Oropesa I (1998) The incidence of adenoviruses in viral conjunctivitis. Rev Cubana Med Trop 50:182–185
pubmed: 10349440
Dawson CR, Hanna L, Togni B (1972) Adenovirus type 8 infections in the United States IV. Observations on the pathogenesis of lesions in severe eye disease. Arch Ophthalmol 87(3):258–268
pubmed: 4335566
Hyde KJ, Berger ST (1988) Epidemic keratoconjunctivitis and lacrimal excretory system obstruction. Ophthalmology 95:1447–1449
pubmed: 3226692
Colon LE (1991) Keratoconjunctivitis due to adenovirus type 8: report on a large outbreak. Ann Ophthalmol 23:63–65
pubmed: 2029116
O’Brien TP, Jeng BH, McDonald M, Raizman MB (2009) Acute conjunctivitis: truth and misconceptions. Curr Med Res Opin 25(8):1953–1961
pubmed: 19552618
Gordon YJ, Gordon RY, Romanowski E, Araullo-Cruz TP (1993) Prolonged recovery of desiccated adenoviral serotypes 5, 8, and 19 from plastic and metal surfaces in vitro. Ophthalmology 100(12):1835–1839 discussion 1839–1840
pubmed: 8259283
American Academy of Ophthalmology (2011) Cornea/External Disease Panel. Preferred Practice Pattern Guidelines: Conjunctivitis-Limited Revision. American Academy of Ophthalmology; San Francisco, CA
Pinna A, Donadu MG, Usai D, Dore S, D'Amico-Ricci G, Boscia F, Zanetti S (2020) In vitro antimicrobial activity of a new ophthalmic solution containing povidone-iodine 0.6% (IODIM®). Acta Ophthalmol. 98(2):e178–e180
pubmed: 31486592
Pelletier JS, Stewart K, Trattler W, Ritterband DC, Braverman S, Samson CM, Liang B, Capriotti JA (2009) A combination povidone-iodine 0.4%/ dexamethasone 0.1% ophthalmic suspension in the treatment of adenoviral conjunctivitis. Adv Ther 26(8):776–783
pubmed: 19756415
Kovalyuk N, Kaiserman I, Mimouni M, Cohen O, Levartovsky S, Sherbany H, Mandelboim M (2017) Treatment of adenoviral keratoconjunctivitis with a combination of povidone-iodine 1.0% and dexamethasone 0.1% drops: a clinical prospective controlled randomized study. Acta Ophthalmol 95(8):e686–e692
pubmed: 28342227
Pepose JS, Ahuja A, Liu W, Narvekar A, Haque R (2018) Randomized, controlled, phase 2 trial of povidone-iodine/dexamethasone ophthalmic suspension for treatment of adenoviral conjunctivitis. Am J Ophthalmol 194:7–15
pubmed: 29787732
Pepose JS, Narvekar A, Liu W, Haque R (2019) A randomized controlled trial of povidone-iodine/dexamethasone ophthalmic suspension for acute viral conjunctivitis. Clin Ophthalmol 13:535–544
pubmed: 30962674
pmcid: 6433103
Holland EJ, Fingeret M, Mah FS (2019) Use of topical steroids in conjunctivitis: a review of the evidence. Cornea 38(8):1062–1067
pubmed: 31276464
Travagli V, Zanardi I, Bocci V (2009) Topical applications of ozone and ozonated oils as anti-infective agents: an insight into the patent claims. Recent Pat Anti-Infect Drug Discovery 4:130–142
Kim HS, Noh SU, Han YW, Kim KM, Kang H, Kim HO, Park YM (2009) Therapeutic effects of topical application of ozone on acute cutaneous woundhealing. J Korean Med Sci 24(3):368–374
pubmed: 19543419
pmcid: 2698179
Murray BK, Ohmine S, Tomer DP, Jensen KJ, Johnson FB, Kirsi JJ, Robison RA, O'Neill KL (2008) Virion disruption by ozone-mediated reactive oxygen species. J Virol Methods 153(1):74–77
pubmed: 18598719
Kashiwagi K, Saito K, Wang YD, Takahashi H, Ishijima K, Tsukahara S (2001) Safety of ozonated solution as an antiseptic of the ocular surface prior to ophthalmic surgery. Ophthalmologica 215:351–356
pubmed: 11528260
Cutarelli A, Carlini G, Sarno F, Nebbioso A, Garofalo F, Altucci L, Corrado F (2019) The role of ozone carried by liposomes in the therapy of infectious and skin-regenerating ocular surface. J Biomed Sci Eng 12:347–353
Montevecchi M, Dorigo A, Cricca M, Checchi L (2013) Comparison of the antibacterial activity of an ozonated oil with chlorhexidine digluconate and povidone-iodine. A disk diffusion test. New Microbiol 36(3):289–302
pubmed: 23912871